Cargando…

Bayesian Model Averaging to Account for Model Uncertainty in Estimates of a Vaccine’s Effectiveness

PURPOSE: Vaccine effectiveness (VE) studies are often conducted after the introduction of new vaccines to ensure they provide protection in real-world settings. Control of confounding is often needed during the analyses, which is most efficiently done through multivariable modeling. When many confou...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliveira, Carlos R, Shapiro, Eugene D, Weinberger, Daniel M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587703/
https://www.ncbi.nlm.nih.gov/pubmed/36281232
http://dx.doi.org/10.2147/CLEP.S378039
_version_ 1784813966355070976
author Oliveira, Carlos R
Shapiro, Eugene D
Weinberger, Daniel M
author_facet Oliveira, Carlos R
Shapiro, Eugene D
Weinberger, Daniel M
author_sort Oliveira, Carlos R
collection PubMed
description PURPOSE: Vaccine effectiveness (VE) studies are often conducted after the introduction of new vaccines to ensure they provide protection in real-world settings. Control of confounding is often needed during the analyses, which is most efficiently done through multivariable modeling. When many confounders are being considered, it can be challenging to know which variables need to be included in the final model. We propose an intuitive Bayesian model averaging (BMA) framework for this task. PATIENTS AND METHODS: Data were used from a matched case–control study that aimed to assess the effectiveness of the Lyme vaccine post-licensure. Cases were residents of Connecticut, 15–70 years of age with confirmed Lyme disease. Up to 2 healthy controls were matched to each case subject by age. All participants were interviewed, and medical records were reviewed to ascertain immunization history and evaluate potential confounders. BMA was used to systematically search for potential models and calculate the weighted average VE estimate from the top subset of models. The performance of BMA was compared to three traditional single-best-model-selection methods: two-stage selection, stepwise elimination, and the leaps and bounds algorithm. RESULTS: The analysis included 358 cases and 554 matched controls. VE ranged between 56% and 73% and 95% confidence intervals crossed zero in <5% of all candidate models. Averaging across the top 15 models, the BMA VE was 69% (95% CI: 18–88%). The two-stage, stepwise, and leaps and bounds algorithm yielded VE of 71% (95% CI: 21–90%), 73% (95% CI: 26–90%), and 74% (95% CI: 27–91%), respectively. CONCLUSION: This paper highlights how the BMA framework can be used to generate transparent and robust estimates of VE. The BMA-derived VE and confidence intervals were similar to those estimated using traditional methods. However, by incorporating model uncertainty into the parameter estimation, BMA can lend additional rigor and credibility to a well-designed study.
format Online
Article
Text
id pubmed-9587703
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-95877032022-10-23 Bayesian Model Averaging to Account for Model Uncertainty in Estimates of a Vaccine’s Effectiveness Oliveira, Carlos R Shapiro, Eugene D Weinberger, Daniel M Clin Epidemiol Short Report PURPOSE: Vaccine effectiveness (VE) studies are often conducted after the introduction of new vaccines to ensure they provide protection in real-world settings. Control of confounding is often needed during the analyses, which is most efficiently done through multivariable modeling. When many confounders are being considered, it can be challenging to know which variables need to be included in the final model. We propose an intuitive Bayesian model averaging (BMA) framework for this task. PATIENTS AND METHODS: Data were used from a matched case–control study that aimed to assess the effectiveness of the Lyme vaccine post-licensure. Cases were residents of Connecticut, 15–70 years of age with confirmed Lyme disease. Up to 2 healthy controls were matched to each case subject by age. All participants were interviewed, and medical records were reviewed to ascertain immunization history and evaluate potential confounders. BMA was used to systematically search for potential models and calculate the weighted average VE estimate from the top subset of models. The performance of BMA was compared to three traditional single-best-model-selection methods: two-stage selection, stepwise elimination, and the leaps and bounds algorithm. RESULTS: The analysis included 358 cases and 554 matched controls. VE ranged between 56% and 73% and 95% confidence intervals crossed zero in <5% of all candidate models. Averaging across the top 15 models, the BMA VE was 69% (95% CI: 18–88%). The two-stage, stepwise, and leaps and bounds algorithm yielded VE of 71% (95% CI: 21–90%), 73% (95% CI: 26–90%), and 74% (95% CI: 27–91%), respectively. CONCLUSION: This paper highlights how the BMA framework can be used to generate transparent and robust estimates of VE. The BMA-derived VE and confidence intervals were similar to those estimated using traditional methods. However, by incorporating model uncertainty into the parameter estimation, BMA can lend additional rigor and credibility to a well-designed study. Dove 2022-10-18 /pmc/articles/PMC9587703/ /pubmed/36281232 http://dx.doi.org/10.2147/CLEP.S378039 Text en © 2022 Oliveira et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Short Report
Oliveira, Carlos R
Shapiro, Eugene D
Weinberger, Daniel M
Bayesian Model Averaging to Account for Model Uncertainty in Estimates of a Vaccine’s Effectiveness
title Bayesian Model Averaging to Account for Model Uncertainty in Estimates of a Vaccine’s Effectiveness
title_full Bayesian Model Averaging to Account for Model Uncertainty in Estimates of a Vaccine’s Effectiveness
title_fullStr Bayesian Model Averaging to Account for Model Uncertainty in Estimates of a Vaccine’s Effectiveness
title_full_unstemmed Bayesian Model Averaging to Account for Model Uncertainty in Estimates of a Vaccine’s Effectiveness
title_short Bayesian Model Averaging to Account for Model Uncertainty in Estimates of a Vaccine’s Effectiveness
title_sort bayesian model averaging to account for model uncertainty in estimates of a vaccine’s effectiveness
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587703/
https://www.ncbi.nlm.nih.gov/pubmed/36281232
http://dx.doi.org/10.2147/CLEP.S378039
work_keys_str_mv AT oliveiracarlosr bayesianmodelaveragingtoaccountformodeluncertaintyinestimatesofavaccineseffectiveness
AT shapiroeugened bayesianmodelaveragingtoaccountformodeluncertaintyinestimatesofavaccineseffectiveness
AT weinbergerdanielm bayesianmodelaveragingtoaccountformodeluncertaintyinestimatesofavaccineseffectiveness